» Articles » PMID: 38161981

The Negative Impact of Levothyroxine Treatment on Urinary Luteinizing Hormone Measurements in Pediatric Patients with Thyroid Disease

Overview
Specialty Endocrinology
Date 2024 Jan 1
PMID 38161981
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Previous studies suggest urinary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) measurements by immunofluorometric assays (IFMA) as noninvasive alternatives to serum assays for puberty assessment. However, these studies excluded patients with other endocrine disorders and those taking medications. Besides, the recent discontinuation of IFMA manufacturing is a concern. We explored the utility of luminometric assays (LIA) for urinary gonadotropins and thyroid-stimulating hormone (TSH) determinations in euthyroid patients with thyroid pathologies.

Methods: We used LIA and IFMA assays to measure serum and first-morning-voided (FMV) urine LH, FSH, and TSH concentrations in euthyroid patients with various thyroid disorders. Of the 47 euthyroid patients with normal serum TSH (S-TSH) levels, 14 were receiving levothyroxine therapy.

Results: FMV total urinary LH (U-LH) concentrations correlated significantly with those measured in serum using either LIA (r=0.67, <.001) or IFMA (r=0.83, =.003) in patients not receiving levothyroxine treatment; however, no significant correlation could be detected in patients receiving levothyroxine regardless of the assay method (for LIA: r=0.50, =.08 and IFMA r=0.44, =.15). Urinary TSH (U-TSH) concentrations correlated poorly with those in serum in both the untreated and the treated groups (r=-0.13, =.49, and r=-0.45, =.11, respectively).

Conclusion: FMV total U-LH determinations by LIA can be used to assess pubertal development in patients with thyroid pathology, provided the euthyroid patient is not on levothyroxine treatment. U-TSH measurements by LIA cannot replace invasive S-TSH measurements at least in patients with normal S-TSH levels. Further research may reveal the utility of U-TSH determinations in patients with elevated S-TSH levels.

References
1.
Demir A, Aydin A, Buyukgebiz A, Stenman U, Hero M . Urinary gonadotropin measurements by enhanced luminometric assays (LIA) for the evaluation of pubertal development. J Pediatr Endocrinol Metab. 2021; 34(7):859-866. DOI: 10.1515/jpem-2020-0598. View

2.
Reiter E, Biggs D, Veldhuis J, Beitins I . Pulsatile release of bioactive luteinizing hormone in prepubertal girls: discordance with immunoreactive luteinizing hormone pulses. Pediatr Res. 1987; 21(4):409-13. DOI: 10.1203/00006450-198704000-00018. View

3.
Kuku S, Harsoulis P, Young J, Fraser T . Concentrations of immunoreactive thyrotrophic hormone in urine of normal subjects, patients with thyroid disorders and hypopituitarism, and after infusion of human thyrotrophic hormone. J Endocrinol. 1974; 62(3):645-55. DOI: 10.1677/joe.0.0620645. View

4.
Bachimanchi B, Vaikkakara S, Sachan A, Praveen Kumar G, Venkatanarasu A, Sai Krishna Chaitanya P . Effect of Adequate Thyroid Hormone Replacement on the Hypothalamo-Pituitary-Gonadal Axis in Premenopausal Women with Primary Hypothyroidism. Eur Thyroid J. 2019; 8(3):152-158. PMC: 6587368. DOI: 10.1159/000495563. View

5.
Zung A, Burundukov E, Ulman M, Glaser T, Rosenberg M, Chen M . The diagnostic value of first-voided urinary LH compared with GNRH-stimulated gonadotropins in differentiating slowly progressive from rapidly progressive precocious puberty in girls. Eur J Endocrinol. 2014; 170(5):749-58. DOI: 10.1530/EJE-14-0010. View